139 related articles for article (PubMed ID: 25625758)
1. Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer.
Mengelbier LH; Karlsson J; Lindgren D; Valind A; Lilljebjörn H; Jansson C; Bexell D; Braekeveldt N; Ameur A; Jonson T; Kultima HG; Isaksson A; Asmundsson J; Versteeg R; Rissler M; Fioretos T; Sandstedt B; Börjesson A; Backman T; Pal N; Øra I; Mayrhofer M; Gisselsson D
Nat Commun; 2015 Jan; 6():6125. PubMed ID: 25625758
[TBL] [Abstract][Full Text] [Related]
2. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression.
Losi L; Baisse B; Bouzourene H; Benhattar J
Carcinogenesis; 2005 May; 26(5):916-22. PubMed ID: 15731168
[TBL] [Abstract][Full Text] [Related]
3. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours.
Khalique L; Ayhan A; Weale ME; Jacobs IJ; Ramus SJ; Gayther SA
J Pathol; 2007 Feb; 211(3):286-95. PubMed ID: 17154249
[TBL] [Abstract][Full Text] [Related]
4. Tumour heterogeneity and the evolution of polyclonal drug resistance.
Burrell RA; Swanton C
Mol Oncol; 2014 Sep; 8(6):1095-111. PubMed ID: 25087573
[TBL] [Abstract][Full Text] [Related]
5. The causes and consequences of genetic heterogeneity in cancer evolution.
Burrell RA; McGranahan N; Bartek J; Swanton C
Nature; 2013 Sep; 501(7467):338-45. PubMed ID: 24048066
[TBL] [Abstract][Full Text] [Related]
6. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
[TBL] [Abstract][Full Text] [Related]
7. Genomic Instability in Cancer: Teetering on the Limit of Tolerance.
Andor N; Maley CC; Ji HP
Cancer Res; 2017 May; 77(9):2179-2185. PubMed ID: 28432052
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral genomic heterogeneity in primary head and neck cancer and corresponding metastases detected by dual-FISH.
Götte K; Schäfer C; Riedel F; Arens N; Hörmann K
Oncol Rep; 2004 Jan; 11(1):17-23. PubMed ID: 14654897
[TBL] [Abstract][Full Text] [Related]
9. Evolutionary hypothesis of telomere length in primary breast cancer and brain tumour patients: a tracer for genomic-tumour heterogeneity and instability.
Mehdipour P; Kheirollahi M; Mehrazin M; Kamalian N; Atri M
Cell Biol Int; 2011 Sep; 35(9):915-25. PubMed ID: 21385157
[TBL] [Abstract][Full Text] [Related]
10. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective.
Heng HH; Bremer SW; Stevens JB; Ye KJ; Liu G; Ye CJ
J Cell Physiol; 2009 Sep; 220(3):538-47. PubMed ID: 19441078
[TBL] [Abstract][Full Text] [Related]
11. Natural and Chemotherapy-Induced Clonal Evolution of Tumors.
Ibragimova MK; Tsyganov MM; Litviakov NV
Biochemistry (Mosc); 2017 Apr; 82(4):413-425. PubMed ID: 28371598
[TBL] [Abstract][Full Text] [Related]
12. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U
Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability.
Bristow RG; Hill RP
Nat Rev Cancer; 2008 Mar; 8(3):180-92. PubMed ID: 18273037
[TBL] [Abstract][Full Text] [Related]
14. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.
Lartigue L; Neuville A; Lagarde P; Brulard C; Rutkowski P; Dei Tos P; Wardelmann E; Debiec-Rychter M; Italiano A; Coindre JM; Chibon F
Eur J Cancer; 2015 Jan; 51(1):75-83. PubMed ID: 25466504
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
16. Intensive chemotherapy with stem cell support-experience in pediatric solid tumours.
Pinkerton CR
Bull Cancer; 1995; 82 Suppl 1():61s-65s. PubMed ID: 7626856
[TBL] [Abstract][Full Text] [Related]
17. Detection of disseminated tumour cells as a potential surrogate-marker for monitoring palliative chemotherapy in colorectal cancer patients.
Staritz P; Kienle P; Koch M; Benner A; von Knebel Doeberitz M; Rudi J; Weitz J
J Exp Clin Cancer Res; 2004 Dec; 23(4):633-9. PubMed ID: 15743034
[TBL] [Abstract][Full Text] [Related]
18. Intratumor heterogeneity: nature and biological significance.
Gerashchenko TS; Denisov EV; Litviakov NV; Zavyalova MV; Vtorushin SV; Tsyganov MM; Perelmuter VM; Cherdyntseva NV
Biochemistry (Mosc); 2013 Nov; 78(11):1201-15. PubMed ID: 24460935
[TBL] [Abstract][Full Text] [Related]
19. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
Brioli A; Melchor L; Cavo M; Morgan GJ
Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
[TBL] [Abstract][Full Text] [Related]
20. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
